-
公开(公告)号:EP0410260A3
公开(公告)日:1992-01-08
申请号:EP90113593.9
申请日:1990-07-16
申请人: ABBOTT LABORATORIES
IPC分类号: C07D521/00 , A61K31/33 , C07D417/12 , C07D213/00
CPC分类号: C07D231/12 , C07D213/38 , C07D233/56 , C07D249/08 , C07D401/12 , C07D417/12
摘要: A renin inhibiting compound having an aminodiol functional group is useful for treating hypertension, congestive heart failure and glaucoma and inhibits retroviral protease.
摘要翻译: 具有氨基二醇官能团的肾素抑制化合物可用于治疗高血压,充血性心力衰竭和青光眼,并抑制逆转录病毒蛋白酶。
-
公开(公告)号:EP0456185A2
公开(公告)日:1991-11-13
申请号:EP91107400.3
申请日:1991-05-07
申请人: ABBOTT LABORATORIES
IPC分类号: C07D277/30 , C07D277/40 , C07D241/08 , C07D417/12 , C07D403/12 , C07D231/12 , C07D295/18 , A61K31/495 , A61K31/425 , A61K38/55
CPC分类号: C07D295/26 , A61K38/00 , C07D277/28 , C07K5/06078
摘要: A renin inhibiting compound of the formula:
wherein R₁ is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl;
R₂ is benzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;
R₃ is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH₃S- or CH₃SCH₂-;
R₄ is isobutyl or cyclopropyl;
R₅ is hydrogen or loweralkyl; and
X is CH₂ or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof; with the proviso that when X is NH and R₃ is 2-amino-4-thiazolyl, then R₄ is cyclopropyl.摘要翻译: 其中R1是4-哌嗪基,1-甲基-4-哌嗪基,1-甲基-1-氧代-4-哌嗪基,2-氧代-4-哌嗪基,4-吗啉基,4-吗啉基, 4-硫代吗啉基或1-甲基-4-高哌嗪基; R2是苄基,2-苯基乙基,1-萘基甲基或2-萘基甲基; R 3是4-噻唑基,2-氨基-4-噻唑基,2-噻唑基,5-噻唑基,1-吡唑基,3-吡唑基,1-咪唑基,正丙基,异丙基,CH 3 S-或CH 3 SCH 2 - R4是异丁基或环丙基; R5是氢或低级烷基; X为CH 2或NH; 或其药学上可接受的盐,酯或前药; 条件是当X是NH且R 3是2-氨基-4-噻唑基时,则R 4是环丙基。
-
公开(公告)号:EP0475206A3
公开(公告)日:1992-08-05
申请号:EP91114542.3
申请日:1991-08-29
申请人: ABBOTT LABORATORIES
发明人: Winn, Martin , De, Biswanath , Zydowsky, Thomas M. , Kerkman, Daniel J. , De Bernardis, John F. , Rosenberg, Saul H. , Shiosaki, Kazumi , Basha, Fatima Z. , Tasker, Andrew S. , Von Geldern, Thomas W. , Kester, Jeffrey A. , Holleman, William H.
IPC分类号: C07D403/12 , A61K31/44 , C07D401/12 , C07D239/42 , C07D257/04 , C07D405/14 , A61K31/495
CPC分类号: C07D239/42 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/14
摘要: Novel pyrimidine, pyridine, pyridazine, pyrazine and triazine compounds are provided of the formula (I).
The compounds of the invention are useful for treating hypertension, edema, renal failure, congestive heart failure, psoriasis and glaucoma, and in the prevention and treatment of atherosclerosis or to treat gastrointestinal disorders associated with enhanced contractility and/or motility of intestinal smooth muscle or to treat contractile disorders of the uterus.-
公开(公告)号:EP0365992A1
公开(公告)日:1990-05-02
申请号:EP89119329.4
申请日:1989-10-18
申请人: ABBOTT LABORATORIES
发明人: De, Biswanath , Dellaria, Joseph F. , Baker, William R. , Zydowsky, Thomas M. , Rosenberg, Saul H. , Jae, Hwan Soo
IPC分类号: C07K5/02 , C07D211/14 , C07D295/15 , C07D295/30 , C07D295/195 , C07D241/08 , C07D403/04 , C07D403/06 , C07D405/14 , C07D411/12 , C07D411/14
CPC分类号: C07D233/64 , A61K38/00 , C07C2601/14 , C07D211/14 , C07D211/76 , C07D213/74 , C07D239/42 , C07D241/04 , C07D241/08 , C07D243/08 , C07D263/10 , C07D263/22 , C07D295/15 , C07D403/06 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/06 , C07K5/06139
摘要: A renin inhibiting compound of the formula:
wherein X is N, O or CH; R 1 is absent or a functional group; A and L are independently selected from absent, C = O, S0 2 and CH 2 ; D is C = O, S0 2 or CH 2 ; Y is N or CH; R 2 is hydrogen, loweralkyl or substituted alkyl; Z is a functional group; R 3 is loweralkyl or substituted alkyl; n is 0 or 1; and T is a mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.摘要翻译: 一种具有下式的肾素抑制化合物:其中X是N,O或CH; R1不存在或官能团; A和L独立地选自C = O,SO 2和CH 2; D为C = O,SO 2或CH 2; Y为N或CH; R2是氢,低级烷基或取代的烷基; Z是功能组; R3是低级烷基或取代的烷基; n为0或1; T是模拟血管紧张素原的Leu-Val切割位点; 或其药学上可接受的盐,酯或前药。
-
公开(公告)号:EP0456185B1
公开(公告)日:1995-05-31
申请号:EP91107400.3
申请日:1991-05-07
申请人: ABBOTT LABORATORIES
IPC分类号: C07D277/30 , C07D277/40 , C07D241/08 , C07D417/12 , C07D403/12 , C07D231/12 , C07D295/18 , A61K31/495 , A61K31/425 , A61K38/55
CPC分类号: C07D295/26 , A61K38/00 , C07D277/28 , C07K5/06078
-
公开(公告)号:EP0456185A3
公开(公告)日:1992-10-14
申请号:EP91107400.3
申请日:1991-05-07
申请人: ABBOTT LABORATORIES
IPC分类号: C07D277/30 , C07D277/40 , C07D241/08 , C07D417/12 , C07D403/12 , C07D231/12 , C07D295/18 , A61K31/495 , A61K31/425 , A61K38/55
CPC分类号: C07D295/26 , A61K38/00 , C07D277/28 , C07K5/06078
摘要: A renin inhibiting compound of the formula:
wherein R₁ is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl;
R₂ is benzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;
R₃ is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH₃S- or CH₃SCH₂-;
R₄ is isobutyl or cyclopropyl;
R₅ is hydrogen or loweralkyl; and
X is CH₂ or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof; with the proviso that when X is NH and R₃ is 2-amino-4-thiazolyl, then R₄ is cyclopropyl.-
7.
公开(公告)号:EP1090908A2
公开(公告)日:2001-04-11
申请号:EP00124275.9
申请日:1996-04-18
申请人: ABBOTT LABORATORIES
发明人: Arendsen, David L. , Baker, William R. , Fakhoury, Stephen A. , Fung, K.L. Anthony , Garvey, David S. , McClellan, William J. , O'Connor, Stephen J. , Prasad, Rajnandan N. , Rockway, Todd W. , Rosenberg, Saul H. , Stein, Herman H. , Shen, Wang , Stout, David M. , Sullivan, Gerard M. , Augeri, David J.
IPC分类号: C07C233/60 , C07D333/20 , C07C233/58 , C07C233/59 , C07C235/40 , A61K31/19 , A61K31/215 , A61K31/38 , A61K31/16
CPC分类号: C07C235/82 , C07C233/58 , C07C233/59 , C07C233/60 , C07C235/40 , C07C2601/04 , C07D333/20
摘要: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
摘要翻译: 本发明提供了用于抑制蛋白质法尼基转移酶和癌基因蛋白Ras的法尼基化的式(II)化合物或其药学上可接受的盐,除用于制备本发明化合物的中间体 这些方法,药物组合物,以及使用这些化合物的方法。
-
公开(公告)号:EP0416393A1
公开(公告)日:1991-03-13
申请号:EP90116225.5
申请日:1990-08-24
申请人: ABBOTT LABORATORIES
发明人: Sham, Hing L. , Rosenberg, Saul H.
IPC分类号: C07K5/06 , C07D233/64 , C07D277/30 , A61K31/415 , A61K31/54 , A61K37/64
CPC分类号: C07D213/40 , A61K38/00 , C07C215/20 , C07C233/36 , C07C233/47 , C07C259/20 , C07C265/08 , C07C271/16 , C07C271/22 , C07C275/24 , C07C309/24 , C07C309/82 , C07C317/28 , C07C317/44 , C07C323/52 , C07C323/60 , C07C2601/14 , C07D205/04 , C07D207/12 , C07D231/12 , C07D233/56 , C07D249/08 , C07D263/20 , C07D263/24 , C07D277/30 , C07D277/42 , C07D295/145 , C07D295/185 , C07D295/205 , C07D295/215 , C07D417/12 , C07D513/04 , C07K5/06191
摘要: A renin inhibiting compound of the formula:
wherein A is a functional group;
W is
(1) -C(O)-,
(2) -CH(OH)- or
(3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl;
U is
(1) -C(O)-,
(2) -CH₂- or
(3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-;
V is
(1) -CH-,
(2) -C(OH)- or
(3) -C(halogen)- with the proviso that v is -CH-when U is -N(R₂)-;
Q is -CH(R₁)- or -C(=CHR 1a )- wherein R₁ is
(1) loweralkyl,
(2) cycloalkylalkyl,
(3) arylalkyl,
(4) (heterocyclic)alkyl,
(5) 1-benzyloxyethyl,
(6) phenoxy,
(7) thiophenoxy or
(8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R 1a is aryl or heterocyclic;
R₃ is a functional group;
R₄ is
(1) loweralkyl,
(2) cycloalkylmethyl or
(3) benzyl;
R₅ is -CH(OH)- or -C(O)-;
R₆ is -CH(OH)- or -C(O)-; and
Z is
(1) lower alkyl,
(2) aryl,
(3) arylalkyl,
(4) cycloalkyl,
(5) cycloalkylalkyl,
(6) heterocyclic or
(7) (heterocyclic)alkyl;
or a pharmaceutically acceptable salt, ester or prodrug thereof.摘要翻译: 下式的肾素抑制化合物:其中A是官能团; W是(1)-C(O) - ,(2)-CH(OH) - 或(3)-N(R 2) - ,其中R 2是氢或低级烷基; U是(1)-C(O) - ,(2)-CH 2 - 或(3)-N(R 2) - ,其中R 2是氢或低级烷基,条件是当W是-CH(OH) U是-CH 2 - ,并且条件是当W是-N(R 2) - 时,U是-C(O) - 或-CH 2 - ; 当U是-N(R 2) - 时,V是(1)-CH-,(2)-C(OH) - 或(3)-C(卤素) - ,条件是v是-CH-。 (1)低级烷基,(2)环烷基烷基,(3)芳基烷基,(4)(杂环)烷基,(5)1-苄氧基乙基,(苄基) 6)苯氧基,(7)苯硫基或(8)苯胺基,条件是当R 1为苯氧基时,B为-CH 2 - 或-CH(OH) - 或A为氢,硫代苯氧基或苯胺基,R 1a为芳基或杂环; R 3是一个官能团; (1)低级烷基,(2)环烷基甲基或(3)苄基; R 5是-CH(OH) - 或-C(O) - ; R 6是-CH(OH) - 或-C(O) - ; (1)低级烷基,(2)芳基,(3)芳基烷基,(4)环烷基,(5)环烷基烷基,(6)杂环或(7)(杂环) 或其药学上可接受的盐,酯或前药。
-
公开(公告)号:EP0341602A2
公开(公告)日:1989-11-15
申请号:EP89108139.0
申请日:1989-05-05
申请人: ABBOTT LABORATORIES
IPC分类号: C07K5/06 , C07D233/64 , C07D231/12 , C07D295/00 , C07D401/12 , C07D401/14 , A61K37/64 , A61K31/395 , C07C103/38 , C07C91/14 , C07C103/50
CPC分类号: C07K5/06191 , A61K38/00 , C07K5/0227 , C07K5/06078
摘要: A renin inhibiting compound of the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof.摘要翻译: 具有下式的肾素抑制化合物:
或其药学上可接受的盐,酯或前药。 -
10.
公开(公告)号:EP1090908A3
公开(公告)日:2001-05-16
申请号:EP00124275.9
申请日:1996-04-18
申请人: ABBOTT LABORATORIES
发明人: Arendsen, David L. , Baker, William R. , Fakhoury, Stephen A. , Fung, K.L. Anthony , Garvey, David S. , McClellan, William J. , O'Connor, Stephen J. , Prasad, Rajnandan N. , Rockway, Todd W. , Rosenberg, Saul H. , Stein, Herman H. , Shen, Wang , Stout, David M. , Sullivan, Gerard M. , Augeri, David J.
IPC分类号: C07C233/60 , C07D333/20 , C07C233/58 , C07C233/59 , C07C235/40 , A61K31/19 , A61K31/215 , A61K31/38 , A61K31/16
CPC分类号: C07C235/82 , C07C233/58 , C07C233/59 , C07C233/60 , C07C235/40 , C07C2601/04 , C07D333/20
摘要: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
摘要翻译: 本发明提供式(II)化合物或其药学上可接受的盐,其可用于抑制蛋白质法呢基转移酶和癌基因蛋白Ras的法呢基化,制备本发明化合物的方法除了可用于 这些方法,药物组合物,以及使用这些化合物的方法。
-
-
-
-
-
-
-
-
-